A
TLANTA — If you want to avoid shingles — a condition that comes with a painful rash — there is a vaccine available. But studies have shown that protection generated by the vaccine declines quickly.
A new vaccine, however, is being considered for approval, and if and when the Food and Drug Administration gives it the green light, its may hit the market with a highly desirably preferential rating from an influential panel of vaccine experts.
Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!
SUBSCRIBE TODAYWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
““A preferential recommendation will make a difference here,” Bresnitz told the committee. “Let the market determine what happens here.”
Translation: Let marketing, not the data, decide.